Aurones as Antidiabetic Agents and Their Prebiotic Activities.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 625, doi. 10.3390/futurepharmacol3030040
- By:
- Publication type:
- Article
Works matching IS 26739879 AND DT 2023 AND VI 3 AND IP 3
Results: 7
1
2
Systemic Inflammasome Biomarkers as Predictors of Diabetic Retinopathy Progression: Evidence from a Pilot Study.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 612, doi. 10.3390/futurepharmacol3030039
- By:
- Publication type:
- Article
3
Cyclodextrin in Vaccines: Enhancing Efficacy and Stability.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 597, doi. 10.3390/futurepharmacol3030038
- By:
- Publication type:
- Article
4
Preferred Therapy for Patients with Hereditary Angioedema during Pregnancy.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 586, doi. 10.3390/futurepharmacol3030037
- By:
- Publication type:
- Article
5
Correction: de Almeida et al. Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity. Future Pharmacol. 2023, 3 , 162–179.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
6
Design of a Cyclodextrin Bioproduction Process Using Bacillus pseudofirmus and Paenibacillus macerans.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 568, doi. 10.3390/futurepharmacol3030035
- By:
- Publication type:
- Article
7
Use of Plant Extracts, Bee-Derived Products, and Probiotic-Related Applications to Fight Multidrug-Resistant Pathogens in the Post-Antibiotic Era.
- Published in:
- Future Pharmacology, 2023, v. 3, n. 3, p. 535, doi. 10.3390/futurepharmacol3030034
- By:
- Publication type:
- Article